ATE223051T1 - Verfahren zur diagnose gutartiger prostataerkrankungen - Google Patents

Verfahren zur diagnose gutartiger prostataerkrankungen

Info

Publication number
ATE223051T1
ATE223051T1 AT96910374T AT96910374T ATE223051T1 AT E223051 T1 ATE223051 T1 AT E223051T1 AT 96910374 T AT96910374 T AT 96910374T AT 96910374 T AT96910374 T AT 96910374T AT E223051 T1 ATE223051 T1 AT E223051T1
Authority
AT
Austria
Prior art keywords
patient
psa
proportion
level
total
Prior art date
Application number
AT96910374T
Other languages
English (en)
Inventor
Albert A Luderer
Grant D Carlson
Robert P Thiel
Thomas F Soriano
William J Kramp
Original Assignee
Albert A Luderer
Grant D Carlson
Robert P Thiel
Thomas F Soriano
William J Kramp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert A Luderer, Grant D Carlson, Robert P Thiel, Thomas F Soriano, William J Kramp filed Critical Albert A Luderer
Application granted granted Critical
Publication of ATE223051T1 publication Critical patent/ATE223051T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96910374T 1995-02-23 1996-02-21 Verfahren zur diagnose gutartiger prostataerkrankungen ATE223051T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/393,214 US5698402A (en) 1995-02-23 1995-02-23 Methods for diagnosing benign prostatic hyperplasia
PCT/US1996/003045 WO1996026441A1 (en) 1995-02-23 1996-02-21 Novel methods for diagnosing benign prostatic diseases

Publications (1)

Publication Number Publication Date
ATE223051T1 true ATE223051T1 (de) 2002-09-15

Family

ID=23553761

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96910374T ATE223051T1 (de) 1995-02-23 1996-02-21 Verfahren zur diagnose gutartiger prostataerkrankungen

Country Status (7)

Country Link
US (3) US5698402A (de)
EP (2) EP1221619A3 (de)
JP (1) JP2001503129A (de)
AT (1) ATE223051T1 (de)
CA (1) CA2213709C (de)
DE (1) DE69623264T2 (de)
WO (1) WO1996026441A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011021A (en) * 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5698402A (en) * 1995-02-23 1997-12-16 Dianon Systems, Inc. Methods for diagnosing benign prostatic hyperplasia
US5710007A (en) * 1995-09-29 1998-01-20 Luderer; Albert A. Methods for diagnosing prostatic adenocarcinoma
US6384022B1 (en) 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US6046180A (en) * 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
RU2218179C2 (ru) 1996-06-17 2003-12-10 Гилфорд Фармасьютикалз Инк. СПОСОБЫ ЛЕЧЕНИЯ РАКА С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ NAALADазы
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
IL121659A (en) * 1996-10-25 2000-07-16 Bayer Ag Method for determining CPSA in a blood sample
US5840501A (en) * 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5981209A (en) * 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6028216A (en) * 1997-12-31 2000-02-22 Guilford Pharmaceuticals Inc. Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
US6121252A (en) * 1998-03-30 2000-09-19 Guilford Pharmaceuticals Inc. Phosphinic acid derivatives
WO1999057306A2 (en) * 1998-05-01 1999-11-11 Queen's University At Kingston Method for diagnosing a vascular condition
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
US6395718B1 (en) * 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
ES2251204T3 (es) 1998-07-06 2006-04-16 Mgi Gp, Inc. Inhibidores de naaladasa utiles como compuestos y composiciones farmaceuticas.
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
EP1151142A2 (de) * 1999-01-28 2001-11-07 Gen-Probe Incorporated Nukleinsäure sequenzen für den nachweis von genetischen markern für krebs in einer biologischen probe
RU2200455C2 (ru) * 2000-06-07 2003-03-20 Черных Виктор Иванович Способ комплексной диагностики заболеваний органов мочеполовой системы мужчин
US6379550B1 (en) 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
EP1178317B1 (de) 2000-07-24 2004-11-10 Health Research, Inc. Verfahren zur Detektion von Prostata-spezifischem Membran-Antigen in Serum
CA2422856C (en) * 2000-09-25 2012-02-07 Abbott Laboratories Methods and kits for decreasing interferences of assay samples containing plasma or serum in specific binding assays by using a large polycation
US20050037447A1 (en) * 2003-07-08 2005-02-17 Yong-Chuan Wong Protein markers for human benign prostatic hyperplasia (BPH)
US20060194230A1 (en) * 2005-01-25 2006-08-31 Baylor College Of Medicine Genetic markers associated with benign prostatic hyperplasia
CN108603883A (zh) * 2016-01-27 2018-09-28 富士胶片和光纯药株式会社 前列腺癌的判定方法
US10585101B2 (en) * 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia
ES2688213T3 (es) * 2016-07-15 2018-10-31 Proteomedix Ag Método para detectar proteínas en muestras humanas y usos de dichos métodos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0635575A1 (de) * 1993-07-22 1995-01-25 Wallac Oy Monoklonale Antikörper gegen Epitope in freiem uber nicht in Alpha-1-antichymotrypsin komplexiertem Prostata spezifisches Antigen
US5698402A (en) * 1995-02-23 1997-12-16 Dianon Systems, Inc. Methods for diagnosing benign prostatic hyperplasia
US5710007A (en) * 1995-09-29 1998-01-20 Luderer; Albert A. Methods for diagnosing prostatic adenocarcinoma

Also Published As

Publication number Publication date
EP0811162A1 (de) 1997-12-10
CA2213709C (en) 2009-01-27
DE69623264T2 (de) 2004-01-22
EP1221619A2 (de) 2002-07-10
EP0811162B1 (de) 2002-08-28
US5912135A (en) 1999-06-15
CA2213709A1 (en) 1996-08-29
US6100049A (en) 2000-08-08
US5698402A (en) 1997-12-16
MX9706415A (es) 1998-07-31
EP0811162A4 (de) 1999-09-01
WO1996026441A1 (en) 1996-08-29
DE69623264D1 (de) 2002-10-02
JP2001503129A (ja) 2001-03-06
EP1221619A3 (de) 2002-08-07

Similar Documents

Publication Publication Date Title
ATE223051T1 (de) Verfahren zur diagnose gutartiger prostataerkrankungen
DE69937368D1 (de) Nachweis von erkrankungen der nieren und behandlung
DE59705683D1 (de) IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG
Baydanoff et al. Age-related changes in the level of circulating elastin-derived peptides in serum from normal and atherosclerotic subjects
DK0433088T3 (da) Monoklonale antistoffer, der reagerer med et humant atheromaassocieret antigen
HUP9701717A2 (hu) Eljárás cPSA-meghatározására
WO1995005604A3 (en) Methods for the diagnosis of alzheimer's disease
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
DE69900998D1 (de) Verfahren zur diagnose adenokarzinom oder benigne pathologie der vorsteherdrüse
ATE68600T1 (de) Satz und verfahren zur diagnose der iganephropathie.
DE69605908D1 (de) Benutzung von reagenzien abgeleitet vom menschlichen metastase unterdrückungs gen kai1 in diagnostischen und gen-terapeutischen verfahren
NO953770L (no) Analysemetode
NZ531712A (en) Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
ATE216495T1 (de) Diagnostisches verfahren für atherosklerosis
ATE217089T1 (de) Diagnostisches verfahren für atherosklerosis
EP0937982A3 (de) Diagnostikum und Therapeutikum zur Behandlung der autoimmunen Hepatitis
DE69204157D1 (de) Verfahren zur bestimmung von anti-rns-antikörpern.
ATE275268T1 (de) Verfahren zur diagnose von sjögren-syndrom
DE60037676D1 (de) Verfahren zur diagnose von rickettsia pulicis
DE59305225D1 (de) Verfahren zur Bestimmung von Thrombose verursachenden Lupus-anticoagulant-Antikörpern
JPH07135973A (ja) 歯周病原性菌由来酵素およびその測定方法並びに当該酵素に対する抗体
DE59510686D1 (de) Komplexverbindungen zur diagnose von gefässerkrankungen
ATE554790T1 (de) Verfahren und zusammensetzungen zur diagnose von asthma
CA2332310A1 (en) Antibody against protein tyrosine phosphatase intracellular domains
AU1726495A (en) Pyridinoline crosslinks as markers of periodontal and peri-implant disease activity

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0811162

Country of ref document: EP